Biodesix, Inc. (BDSX) Earnings Call Analysis
NASDAQ · Healthcare · Diagnostics & Research
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Biodesic (BDSX) Q1 2026: Diagnostic Test Volumes Jump 29% as Primary Care Channel Expands Reach
June 16, 2026
-
Biodesix (BDSX) Q2 2025: Development Services Revenue Jumps 53% as Primary Care Push Gains Traction
June 16, 2026
-
Biodesics (BDSX) Q3 2025: Primary Care Test Orders Jump 75% as Sales Expansion Drives Adoption
June 16, 2026
-
Biodesix (BDSX) Q4 2025: Lung Diagnostics Revenue Jumps 46% as Primary Care Channel Expands
June 15, 2026
-
BDSX Q4 2024: Diagnostic Development Services Revenue Jumps 70%, Expanding Multimodal Growth Path
July 06, 2025
-
BDSX Q1 2025: Sales Rep Count Drops 8%, Delaying Primary Care Expansion and Revenue Ramp
July 06, 2025
-
Biodesix (BDSX) Q3 2024: Lung Diagnostic Revenue Climbs 40% as Sales Force Expansion Reignites Growth Trajectory
November 01, 2024
-
BDSX Q2 2024: Biopharma Services Revenue Jumps 228% as Lung Diagnostics Scales
August 07, 2024
-
Biodesix (BDSX) Q1 2024: Lung Diagnostic Test Volume Up 57%, Margin Leverage Signals Profit Path
May 08, 2024
-
Biodesix (BDSX) Q4 2023: Lung Test Volumes Surge 65% as Margin Expansion Accelerates
March 01, 2024